Anti-Seizure Medications Flashcards
Characteristics/types of partial seizures
- Simple partial – 10%
- Key feature is preservation of consciousness
- Usually of cortical origin in a restricted region
- Complex partial – 35%
- Loss of or impaired consciousness
- Often psychomotor with involvement of limbic regions
- Secondary generalized
- Loss of consciousness; includes other areas/muscle groups
Characteristics of tonic-clonic seizures
- Tonic-clonic (grand mal) – 30%
- Presentation: tonic phase (rigid extension of trunk and limbs) + clonic phase (rhythmic contraction of arms and legs), loss of postural control, LOC, abnormal behavior, confusion
- Mechanism: Initiation occurs locally with loss of GABA inhibitory tone; propagation due to decreased GABA tone over a large area / increased response to glutamate
Characteristics of absence seizures
- Absence (Petit mal) – 10%
- Presentation: usually begin in childhood and cease by age 20; normal muscle tone, impaired consciousness with staring spells
- Mechanism: Oscillatory stimulation of thalamic-cortical circuitry with inappropriate activation of low-threshold _T-type Ca2+ channels _
General MOA of anti-seizure drugs
- elevating seizure threshold = membrane stabilization
- decrease T-type Ca2+ channel currents
- enhancement of GABA action
- limiting propogation (reduced synaptic transmission)
Pathophysiology of seizures (opportunities for pharmacotherapeutic intervention)
- Traceable to unstable neuronal membrane (focal epileptogenesis ==> initiation).
- Paroxysmal discharges that can recruit and synchronize a large population of cortical neurons or neurons in thalamic region.
- Enhancement of excitatory neurotransmitters (primarily glutamate) OR
- deficiency of inhibitory neurotransmitters (primarily GABA) ==> propagation of abnormal activity
Antiepileptic drugs used in Primary generalized tonic-clonic seizures
- Valproate
- Lamotrigine
- Levetiracetam
- alternative: phenytoin
Antiepileptic drugs used in partial seizures (including secondarily general)
- Carbamazepine (or Oxcarazepine)
- Lamotrigine
- Levetiracetam
Antiepileptic drugs used in absence seizures
- Ethosuximide
- Valproate
Antiepileptic drugs used in atypical absence, myoclonic, atonic seizures
- Valproate
- Lamotrigine
- Levetiracetam
Characteristics/examples of drugs that inhibit sodium channel [VSSC] fxn
- use-dependent blockade of excited cells via binding of inactivated state to prolong refactoriness
- Phenytoin, carbamazepine, lamotrigine, and topiramate block voltage dependent sodium channels and reduce repetitive firing, thus better at controlling tonic-clonic seizures
Example of drug that decreases T-type currents
- ethosuximide
Examples of drugs that enhance GABA action
- Benzodiazepines and phenobarbital
- Vigabatrin [Sabril] inhibits inactivation of GABA by GABA-transaminase
- Tiagabine [Gabatril] blocks the reuptake of GABA at the synapse
- Gabapentin alters GABA neurochemistry (metabolism, release, or reuptake) increasing GABA levels in brain.
Drugs used in status epilepticus
- diazepam
- lorazepam
- midazolam
- Treatment
- Initial therapy = IV Lorazepam until seizures stop, then phenytoin
- If seizures persist, IV phenobarbital, then pentobarbital until seizures stop
- If seizures persist, then pentobarbital or propofol with pressor support
Definition of status epilepticus
A state of recurrent, major motor seizures between which the patient does not regain consciousness; death occurs in 5-20% of untreated cases from respiratory arrest or circulatory collapse
Characteristics of Carbamazepine
Mechanism
Suppresses repetitive action potential firing by blocking Na2+ channels
Use
Drug of choice for partial seizures; also useful in tonic-clonic seizures
May make absence or myoclonic seizures worse
Side effects
CYP450 inducer; clearance can increase 2-fold in the first month of treatment due to self-induction of metabolism
Dose-related: Diplopia, Ataxia, nausea/vomiting, drowsiness, hyponatremia
Rare: Stevens-Johnson Syndrome – risk associated with HLA-B1502 allele and Asian ancestry, aplastic anemia, agranulocytosis, hepatotoxicity